THE EUROPEAN Commission has banned Glaxo Wellcome's dual pricing system in Spain, where the company requires Spanish wholesalers to pay a higher price for pharmaceuticals, which they export to other Member States, than when reselling the same products locally.

Glaxo had hoped to reduce parallel trading of its products within the European Union, but its move sparked the Commission into action; it has consistently defended the right of distributors in a variety of sectors to partake in such grey market activities, limiting the right of ...

Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.